Biomonitoring Equivalents for benzene

Regulatory Toxicology and Pharmacology

Volumn 62, Issue 1, 2012, Pages 62-73

  Hays, Sean M ^a,b   Pyatt, David W ^a,b   Kirman, Chris R ^a   Aylward, Lesa L ^a  

^a LLP   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Benzene; Biomonitoring; Biomonitoring Equivalent; Pharmacokinetics; Risk assessment

Indexed keywords

ALBUMIN; BENZENE; CIGARETTE SMOKE; GASOLINE; HEMOGLOBIN; PETROLEUM DERIVATIVE;

ARTICLE; BIOLOGICAL MONITORING; BIOMONITORING EQUIVALENT; BLOOD LEVEL; BLOOD TOXICITY; ENVIRONMENTAL EXPOSURE; HALF LIFE TIME; HEALTH HAZARD; HUMAN; LONG TERM EXPOSURE; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; TOXICOKINETICS; TOXICOLOGICAL PARAMETERS; URINE LEVEL;

ANIMALS; BENZENE; BIOLOGICAL MARKERS; CARCINOGENS; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; HUMANS; REFERENCE VALUES; RISK ASSESSMENT;

EID: 84855508279     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2011.12.001     Document Type: Article

References (92)

1. ACGIH 2001. Benzene Biological Exposure Index (BEI) Documentation. http://www.acgih.org/Products/beiintro.htm.
2. 3H-benzene metabolism in rabbit bone marrow. Life Sciences 1979, 25:567-572.
3. Toxicological Profile for Benzene 2007, ATSDR (Agency for Toxic Substance and Disease Registry), US Department of Health and Human Services.
4. Aylward L.L., Kirman C.R., Blount B.C., Hays S.M. Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs) - Application of steady-state PBPK model solutions. Regulatory Toxicology and Pharmacology 2010, 58(1):33-44.
5. Aylward L.L., Hays S.M. Biomonitoring Equivalents (BE) dossier for 2, 4-dichlorophenoxyacetic acid (2,4-D) (CAS No. 94-75-7). Regulatory Toxicology and Pharmacology 2008, 51:S37-S48.
6. Baarson K.A., Snyder C.A., Albert R.E. Repeated exposure of C57BL mice to inhaled benzene at 10ppm markedly depressed erythropoietic colony formation. Toxicology Letters 1984, 20:337-342.
7. Bois F.Y., Jackson E.T., Pekari K., Smith M.T. Population toxicokinetics of benzene. Environmental Health Perspectives 1996, 104(Suppl 6):1405-1411.
8. Boogaard P.J., van Sittert N.J. Suitability of S-phenyl mercapturic acid and trans-trans-muconic acid as biomarkers for exposure to low concentrations of benzene. Environmental Health Perspectives 1996, 104(Suppl 6):1151-1157.
9. Brown E.A., Shelley M.L., Fisher J.W. A pharmacokinetic study of occupational and environmental benzene exposure with regard to gender. Risk Analysis: An Official Publication of the Society for Risk Analysis 1998, 18:205-213.
10. Brugnone F., Perbellini L., Romeo L., Cerpelloni M., Bianchin M., Tonello A. Benzene in blood as a biomarker of low level occupational exposure. The Science of the Total Environment 1999, 235:247-252.
11. CA (California), 2000. Chronic Toxicity Summary: Benzene. http://oehha.ca.gov/air/chronic_rels/pdf/71432.pdf.
12. Cole C.E., Tran H.T., Schlosser P.M. Physiologically based pharmacokinetic modeling of benzene metabolism in mice through extrapolation from in vitro to in vivo. Journal of Toxicology & Environmental Health Part A: Current Issues 2001, 62:439-465.
13. Cox L.A. Reassessing benzene risks using internal doses and Monte-Carlo uncertainty analysis. Environmental Health Perspectives 1996, 104(Suppl 6):1413-1429.
14. Dempster A.M., Snyder C.A. Short term benzene exposure provides a growth advantage for granulopoietic progenitor cells over erythroid progenitor cells. Archives of Toxicology 1990, 64:539-544.
15. Dempster A.M., Snyder C.A. Kinetics of granulocyte and erythroid progenitor cells are affected differently by short-term, low-level benzene exposure. Archives of Toxicology 1991, 65:556-561.
16. Fustinoni S., Buratti M., Campo L., Colombi A., Consonni D., Pesatori A.C., Bonzini M., Farmer P., Garte S., Valerio F., Merlo D.F., Bertazzi P.A. Urinary t,t-muconic acid, S-phenyl mercapturic acid and benzene as biomarkers of low benzene exposure. Chemico-Biological Interactions 2005, 153-154:253-256.
17. Gad-El Karim M.M., Ramanujam V.M., Legator M.S. trans,trans-Muconic acid, an open-chain urinary metabolite of benzene in mice. Quantification by high-pressure liquid chromatography. Xenobiotica; The Fate of Foreign Compounds in Biological Systems 1985, 15:211-220.
18. Ghittori S., Fiorentino M.L., Maestri L., Cordioli G., Imbriani M. Urinary excretion of unmetabolized benzene as an indicator of benzene exposure. Journal of Toxicology and Environmental Health 1993, 38:233-243.
19. Ghittori S., Maestri L., Fiorentino M.L., Imbriani M. Evaluation of occupational exposure to benzene by urinalysis. International Archives of Occupational and Environmental Health 1995, 67:195-200.
20. Green J.D., Snyder C.A., LoBue J., Goldstein B.D., Albert R.E. Acute and chronic dose/response effects of inhaled benzene on multipotential hematopoietic stem (CFU-S) and granulocyte/macrophage progenitor (GM-CFU-C) cells in CD-1 mice. Toxicology and Applied Pharmacology 1981, 58:492-503.
21. Hays S.M., Becker R., Leung H.W., Aylward L.L., Pyatt D.W. Biomonitoring Equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective. Regulatory Toxicology and Pharmacology 2007, 47:96-109.
22. Hays S.M., Aylward L.L., LaKind J.S., Bartels M.J., Barton H.A., Boogaard P.J., Brunk P.J., Dizio S., Dourson M., Goldstein D.A., Lipscomb J., Kilpatrick M.E., Krewski D., Krishnan K., Nordberg M., Okino M., Tan Y.-M., Viau C., Yager J.W. Guidelines for the derivation of Biomonitoring Equivalents: Report from the Biomonitoring Equivalents Expert Workshop. Regulatory Toxicology and Pharmacology 2008, 51:S4-S15.
23. Hays S.M., Aylward L.L. Biomonitoring Equivalents (BE) dossier for acrylamide (AA) (CAS No. 79-06-1). Regulatory Toxicology and Pharmacology 2008, 51:S57-S67.
24. Hays S.M., Aylward L.L. Using Biomonitoring Equivalents to interpret human biomonitoring data in a public health risk context. Journal of Applied Toxicology 2009, 29:275-288.
25. Huff J.E., Haseman J.K., DeMarini D.M., Eustis S., Maronpot R.R., Peters A.C., Persing R.L., Chrisp C.E., Jacobs A.C. Multiple-site carcinogenicity of benzene in Fischer 344 rats and B6C3F1 mice. Environmental Health Perspectives 1989, 82:125-163.
26. Ikeda M. Solvents in urine as exposure markers. Toxicology Letters 1999, 108(2-3):99-106.
27. Irons R.D., Heck H.d.A., Moore B.J., Muirhead K.A. Effects of short-term benzene administration on bone marrow cell cycle kinetics in the rat. Toxicology and Applied Pharmacology 1979, 51:399-409.
28. Irons R.D., Dent J.G., Edgar T.S., et al. In vivo metabolism and covalent binding of benzene in bone-marrow. Toxicology and Applied Pharmacology 1979, 48:166.
29. Irons R.D. Benzene-induced myelotoxicity: application of flow cytofluorometry for the evaluation of early proliferative change in bone marrow. Environmental Health Perspectives 1981, 39:39-49.
30. Irons R.D., Stillman W.S., Colagiovanni D.B., Henry V.A. Synergistic action of the benzene metabolite hydroquinone on myelopoietic stimulating activity of granulocyte/macrophage colony-stimulating factor in vitro. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:3691-3695.
31. Irons R.D. Leukemogenesis as a toxic response. Comprehensive Toxicology 1997, 175-199. Elsevier Science Ltd., New York. I.G. Sipes (Ed.).
32. AC I.U.P. Biological monitoring for exposure to volatile organic compounds (VOCs). Pure and Applied Chemistry 2000, 72:385-436.
33. Kalf G.F. Recent advances in the metabolism and toxicity of benzene. Critical Reviews in Toxicology 1987, 18(2):141-159.
34. Keller K.A., Snyder C.A. Mice exposed in utero to 20ppm benzene exhibit altered numbers of recognizable hematopoietic cells up to seven weeks after exposure. Fundamental and Applied Toxicology 1988, 10:224-232.
35. Kim S., Vermeulen R., Waidyanatha S., Johnson B.A., Lan Q., Rothman N., Smith M.T., Zhang L., Li G., Shen M., Yin S., Rappaport S.M. Using urinary biomarkers to elucidate dose-related patterns of human benzene metabolism. Carcinogenesis 2006, 27:772-781.
36. LaKind J.S., Aylward L.L., Brunk C., DiZio S., Dourson M., Goldstein D.A., Kilpatrick M.E., Krewski D., Bartels M.J., Barton H.A., Boogaard P.J., Lipscomb J., Krishnan K., Nordberg M., Okino M., Tan Y.M., Viau C., Yager J.W., Hays S.M. Guidelines for the communication of Biomonitoring Equivalents: Report from the Biomonitoring Equivalents Expert Workshop. Regulatory Toxicology and Pharmacology 2008, 51:S16-S26.
37. Lawrie C.A., Renwick A.G. The effect of saccharin ingestion on the excretion of microbial amino acid metabolites in rat and man. Toxicology and Applied Pharmacology 1987, 91:415-428.
38. Lin Y.S., Vermeulen R., Tsai C.H., Waidyanatha S., Lan Q., Rothman N., Smith M.T., Zhang L., Shen M., Li G., Yin S., Kim S., Rappaport S.M. Albumin adducts of electrophilic benzene metabolites in benzene-exposed and control workers. Environmental Health Perspectives 2007, 115:28-34.
39. Lindsey R., Bender R., Osheroff N. Stimulation of topoismerase II-mediated DNA cleavage by benzene metabolites. Chemico-Biological Interactions 2005, 1:153-154. (197-205).
40. Longacre S.L., Kocsis J.J., Snyder R.S. Influence of strain differences in mice on the metabolism and toxicity of benzene. Toxicology and Applied Pharmacology 1980, 60:398-409.
41. 6]benzene to rats. Carcinogenesis 1993, 14:1921-1925.
42. 6]benzene. Cancer Research 1994, 54:4907-4914.
43. McMahon T.F., Medinsky M.A., Birnbaum L.S. Age-related changes in benzene disposition in male C57BL/6N mice described by a physiologically based pharmacokinetic model. Toxicology Letters 1994, 74:241-253.
44. Medinsky M.A., Sabourin P.J., Lucier G., Birnbaum L.S., Henderson R.F. A toxikinetic model for simulation of benzene metabolism. Experimental Pathology 1989, 37:150-154.
45. Meek M.E.B., Klaunig J.E. Proposed mode of action of benzene-induced leukemia: Interpreting available data and identifying critical data gaps for risk assessment. Chemico-Biological Interactions 2010, 184:279-285.
46. Mondrala S., Eastmond D.A. Topoisomerase II inhibition by the bioactivated benzene metabolite hydroquinone involves multiple mechanisms. Chemico-Biological Interactions 2010, 184:259-268.
47. Human Biomonitoring for Environmental Chemicals 2006, NRC (National Research Council), National Academy Press, Washington, DC.
48. Ong C.N., Lee B.L. Determination of benzene and its metabolites: application in biological monitoring of environmental and occupational exposure to benzene. Journal of Chromatography. B, Biomedical Applications 1994, 660:1-22.
49. Ong C.N., Kok P.W., Lee B.L., Shi C.Y., Ong H.Y., Chia K.S., Lee C.S., Luo X.W. Evaluation of biomarkers for occupational exposure to benzene. Occupational and Environmental Medicine 1995, 52:528-533.
50. Ong C.N., Kok P.W., Ong H.Y., Shi C.Y., Lee B.L., Phoon W.H., Tan K.T. Biomarkers of exposure to low concentrations of benzene: a field assessment. Occupational and Environmental Medicine 1996, 53:328-333.
51. Parke D.V., Williams R.T. Studies in detoxication: 30. The metabolism of benzene. (a) The determination of benzene. (b) The elimination of unchanged benzene by rabbits. Biochemical Journal 1950, 46:236-243.
52. 1]benzene. Biochemical Journal 1953, 54:231-238.
53. Pekari K., Vainiotalo S., Heikkila P., Palotie A., Luotamo M., Riihimaki V. Biological monitoring of occupational exposure to low levels of benzene. Scandinavian Journal of Work, Environment and Health 1992, 18:317-322.
54. Perbellini L., Princivalle A., Cerpelloni M., Pasini F., Brugnone F. Comparison of breath, blood and urine concentrations in the biomonitoring of environmental exposure to 1,3-butadiene, 2,5-dimethylfuran, and benzene. International Arch.of Occupational and Environmental Health 2003, 76:461-466.
55. + T lymphocytes'. Toxicology and Applied Pharmacology 1998, 149:178-184.
56. + bone marrow cell survival. Blood 1999, 93:3302-3308.
57. Pyatt D.W., Yang J., Stillman W.S., Irons R.D. Inhibition of NF-kB in primary human CD19+ B lymphocytes by hydroquinone. The Toxicologist 1999, 48:824.
58. Pyatt D. Benzene and hematopoietic malignancies. Clinics in occupational and environmental medicine 2004, 4:529-555. (vii).
59. Rana S.V.S., Verma Y. Biochemical toxicity of benzene. Journal of Environmental Biology 2005, 26:157-168.
60. Rappaport S.M., Waidyanatha S., Qu Q., Shore R., Jin X., Cohen B., Chen L.C., Melikian A.A., Li G., Yin S., Yan H., Xu B., Mu R., Li Y., Zhang X., Li K. Albumin adducts of benzene oxide and 1,4-benzoquinone as measures of human benzene metabolism. Cancer Research 2002, 62:1330-1337.
61. Rappaport S.M., Yeowell-O'Connell K., Smith M.T., Dosemeci M., Hayes R.B., Zhang L., Li G., Yin S., Rothman N. Non-linear production of benzene oxide-albumin adducts with human exposure to benzene. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 2002, 778:367-374.
62. Renwick A.G., Thakrar A., Lawrie C.A., George C.F. Microbial amino acid metabolites and bladder cancer: no evidence of promoting activity in man. Human Toxicology 1988, 7:267-272.
63. Renz J.F., Kalf G.F. A role for interleukin-1 in benzene-induced hematotoxicity: inhibition of the conversion of pre-IL-1a to mature cytokine in murine macrophages by hydroquinone and prevention of benzene-induced hematotoxicity in mice by IL-1-alpha. Blood 1991, 78:938-944.
64. Renz J.F., Kalf G.F. A role for interleukin-1 in benzene-induced hematotoxicity. Experimental Hematology 1992, 20:119.
65. Ross D. Metabolic basis of benzene toxicity. European Journal of Haematology. Supplementum 1996, 60:111-118.
66. Ross D., Siegel D., Schattenberg D.G., Sun X.M.M., Moran J.L. Cell-specific activation and detoxification of benzene metabolites in mouse and human bone marrow: Identification of target cells and a potential role for modulation of apoptosis in benzene toxicity. Environmental Health Perspectives 1996, 104(Suppl 6):1177-1182.
67. Rothman N., Li G.L., Dosemeci M., Bechtold W.E., Marti G.E., Wang Y.Z., Linet M., Xi L.Q., Lu W., Smith M.T., Titenko-Holland N., Zhang L.P., Blot W., Yin S.N., Hayes R.B. Hematotoxicity among Chinese workers heavily exposed to benzene. American Journal of Industrial Medicine 1996, 29:236-246.
68. Rozen M.G., Snyder C.A., Albert R.E. Depressions in B- and T-lymphocyte mitogen-induced blastogenesis in mice exposed to low concentrations of benzene. Toxicology Letters 1984, 20:343-349.
69. Sato A., Nakajima T., Fujiwara Y., Murayama N. Kinetic studies on sex difference in susceptibility to chronic benzene intoxication - with special reference to body fat content. British Journal of Industrial Medicine 1975, 32:321-328.
70. Sexton K., Needham L.L., Pirkle J.L. Human biomointoring of environmental chemicals. American Scientist 2004, 92:38-45.
71. Sexton K., Adgate J.L., Church T.R., Ashley D.L., Needham L.L., Ramachandran G., Fredrickson A.L., Ryan A.D. Children's exposure to volatile organic compounds as determined by longitudinal measurements in blood. Environmental Health Perspectives 2005, 113(3):342-349.
72. Sinclair G.C., Gray C.N., Sherwood R.J. Structure and validation of a pharmacokinetic model for benzene. American Industrial Hygiene Association Journal 1999, 60:249-258.
73. Snyder C.A., Goldstein B.D., Sellakumar A.R., Wolman S.R., Bromberg I., Erlichman M.N., Laskin S. Hematotoxicity of inhaled benzene to sprague-dawley rats and AKR mice at 300ppm. Journal of Toxicology and Environmental Health 1978, 4:605-618.
74. Snyder C.A., Baarson K.A., et al. Ingestion of ethanol increases the hematotoxicity of inhaled benzene in C57BL mice. Bulletin of Environmental Contamination and Toxicology 1981, 27(2):175-180.
75. Snyder R.S., Longacre S.L., Sammett D., Witmer C.M., Kocsis J.J. Relationship between the toxicity and metabolism of benzene. Advances in Modern Environmental Toxicology Volume 4: Carcinogenicity and Toxicity of Benzene 1983, 23-36. Princeton Scientific Publishers Inc., Princeton. M.A. Mehlman (Ed.).
76. Srbova J., Teisinger J., Kramovsky S. Absorption and elimination of inhaled benzene in man. Archives of Industrial Hygiene and Occupational Medicine 1950, 2:1-8.
77. Sun J.D., Medinsky M.A., Birnbaum L.S., Lucier G., Henderson R.F. Benzene hemoglobin adducts in mice and rats: characterization of formation and physiological modeling. Fundamental and Applied Toxicology: Official Journal of the Society of Toxicology 1990, 15:468-475.
78. TCEQ (Texas Commission of Environmental Quality). 2007. Development Support Document: Benzene. http://www.tceq.state.tx.us/assets/public/implementation/tox/dsd/final/benzene_71-43-2_final_10-15-07.pdf.
79. Tolentino D., Zenari E., Dall'Olio M., Ruani G., Gelormini A., Mirone G. Application of statistical models to estimate the correlation between urinary benzene as biological indicator of exposure and air concentrations determined by personal monitoring. AIHA Journal: a Journal for the Science of Occupational and Environmental Health and Safety 2003, 64:625-629.
80. Travis C.C., Quillen J.L., Arms A.D. Pharmacokinetics of benzene. Toxicology and Applied Pharmacology 1990, 102:400-420.
81. Tsai S.P., Wen C.P., Weiss N.S., Wong O., McClellan W.A., Gibson R.L. Retrospective mortality and medical surveillance studies of workers in benzene areas of refineries. Journal of Occupational Medicine 1983, 25(9):685-692.
82. USEPA, 2000. IRIS, Integrated Risk Information System: Benzene. Cancer Potency Factor. http://cfpub.epa.gov/ncea/iris/index.cfm.
83. USEPA, 2003. IRIS, Integrated Risk Information System: Benzene. _I. Chronic Health Hazard Assessments for Noncarcinogenic Effects. http://cfpub.epa.gov/ncea/iris/index.cfm.
84. USEPA, 2006. Acute Exposure Guideline Levels (AEGLs). http://www.epa.gov/opptintr/aegl/pubs/results72.htm.
85. Valentine J.L., Lee S.S., Seaton M.J., Asgharian B., Farris G., Corton J.C., Gonzalez F.J., Medinsky M.A. Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression. Toxicology and Applied Pharmacology 1996, 141:205-213.
86. Waidyanatha S., Rothman N., Fustinoni S., Smith M.T., Hayes R.B., Bechtold W., Dosemeci M., Guilan L., Yin S., Rappaport S.M. Urinary benzene as a biomarker of exposure among occupationally exposed and unexposed subjects. Carcinogenesis 2001, 22:279-286.
87. Wallace L. Environmental exposure to benzene: an update. Environmental Health Perspectives 1996, 104(6):1129-1136.
88. Watanabe K.H., Bois F.Y. Interspecies extrapolation of physiological pharmacokinetic parameter distributions. Risk Analysis: an Official Publication of the Society for Risk Analysis 1996, 16:741-754.
89. Yeowell-O'Connell K., Rothman N., Smith M.T., Hayes R.B., Li G., Waidyanatha S., Dosemeci M., Zhang L., Yin S., Titenko-Holland N., Rappaport S.M. Hemoglobin and albumin adducts of benzene oxide among workers exposed to high levels of benzene. Carcinogenesis 1998, 19:1565-1571.
90. Yeowell-O'Connell K., Rothman N., Waidyanatha S., Smith M.T., Hayes R.B., Li G., Bechtold W.E., Dosemeci M., Zhang L., Yin S., Rappaport S.M. Protein adducts of 1,4-benzoquinone and benzene oxide among smokers and nonsmokers exposed to benzene in China. Cancer Epidemiology, Biomarkers & Prevention: a Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2001, 10:831-838.
91. Yokley K., Tran H.T., Pekari K., Rappaport S., Riihimaki V., Rothman N., Waidyanatha S., Schlosser P.M. Physiologically-based pharmacokinetic modeling of benzene in humans: a Bayesian approach. Risk Analysis: An Official Publication of the Society for Risk Analysis 2006, 26:925-943.
92. Yoon B.I., Hirabayashi Y., Kawasaki Y., Kodama Y., Kaneko T., Kim D.Y., Inoue T. Mechanism of action of benzene toxicity: cell cycle suppression in hemopoietic progenitor cells (CFU-GM). Experimental Hematology 2001, 29:278-285.